Galmed Pharmaceuticals Reports Third Quarter Financial Results
Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is excited to announce its financial results for the third quarter of 2025, alongside notable advancements in its business objectives. As a company dedicated to the development of therapeutic solutions for liver and gastrointestinal cancers, Galmed continues to drive innovation in the biopharmaceutical sector.
Financial Overview of Q3 2025
In the financial overview, the company reported significant progress in various financial metrics. As of September 30, 2025, Galmed's cash and cash equivalents, along with short-term deposits, totaled approximately $19.2 million, a notable increase from the $15.4 million recorded at the end of 2024.
Despite the positive cash flow, the company reported a net loss of around $2.0 million, which translates to $0.33 per share. This figure reflects a slight increase in losses compared to the $1.9 million net loss or $2.31 per share in the same quarter of the previous year.
Research and Development Efforts
Galmed's investment in research and development showcased an increase in expenditures. The company allocated approximately $1.1 million towards R&D in Q3 2025, compared to $0.7 million in the prior year's quarter. The uptick in spending is primarily attributed to ongoing clinical and preclinical studies aimed at bolstering the efficacy of its lead compound, Aramchol.
Furthermore, the company reported approximately $1.0 million in general and administrative expenses for the quarter, a decrease from the $1.3 million in Q3 2024. This reduction can be linked to a cutback in salaries and benefits expenses as part of cost management strategies.
Recent Developments in Business Strategy
In November 2025, Galmed announced promising findings from its collaboration with Virginia Commonwealth University (VCU). This joint effort evaluated how Aramchol can help mitigate drug resistance in gastrointestinal cancers. The top-line results indicated that a combination of Aramchol with existing treatments effectively enhances the elimination of tumor cells both in vivo and in vitro.
Moreover, Galmed presented significant results from its Phase 1 AM-001 study, which assessed the bioavailability of Aramchol Meglumine. These findings mark a pivotal step in the progress of Aramchol as a viable treatment option for patients.
Throughout 2025, the company secured approximately $9.3 million through equity financing and At-the-Market (ATM) facilities, enhancing its operational liquidity and funding for future clinical trials.
Future Outlook and Growth Strategy
Galmed Pharmaceuticals remains focused on advancing its core product, Aramchol. Aside from the liver disease market, the company is actively seeking to expand its product pipeline targeting oncological indications beyond NASH and fibrosis. This strategic direction positions Galmed to capitalize on the growing demand for innovative therapies in the biopharmaceutical industry.
The company’s commitment to pursuing novel treatment approaches is underscored by its ongoing clinical efforts and robust financial standing. Galmed aims to harness its insights and operational strength to enhance its growth trajectory while actively exploring partnerships and opportunities that align with its mission.
About Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals is a biopharmaceutical company focused on developing Aramchol, particularly for treating liver diseases. The company’s extended strategy involves seeking innovative approaches and diversifying its product offerings, primarily within cardiometabolic conditions and other unique drug candidates that complement its expertise in therapeutic development.
Frequently Asked Questions
What were the significant financial metrics for Galmed in Q3 2025?
Galmed reported $19.2 million in total cash and cash equivalents, a net loss of $2.0 million, and R&D expenses of approximately $1.1 million.
What did Galmed announce regarding Aramchol in collaboration with VCU?
Galmed announced that a combination therapy using Aramchol proved effective in combating drug resistance in gastrointestinal cancers during its study with VCU.
What is the future direction of Galmed Pharmaceuticals?
Galmed is focused on advancing the development of Aramchol for liver diseases and exploring additional oncological indications in its product pipeline.
How much funding did Galmed raise through equity facilities in 2025?
Galmed successfully raised approximately $9.3 million throughout 2025 via its equity line and ATM facilities.
What is the main focus of Galmed Pharmaceuticals?
The primary focus is on developing Aramchol as a treatment for liver diseases, while also targeting broader oncological indications and investing in innovative therapies.
